Clinical Trial

The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.
Trial Details
NCT Number NCT05778253
Lead Sponsor Second Xiangya Hospital of Central South University
Collaborators: Shanghai OrigiMed Co., Ltd.
Conditions Lung Squamous Cell Carcinoma
Enrollment 50 participants
Start Date 2023-03-23
Primary Completion 2028-09-23 (estimated)
Study Completion 2029-09-23 (estimated)
Updated on ClinicalTrials.gov 2023-03-21